{"nctId":"NCT00837265","briefTitle":"Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","startDateStruct":{"date":"2008-08-21","type":"ACTUAL"},"conditions":["Chemotherapy-induced Neutropenia"],"count":334,"armGroups":[{"label":"Pilot Phase: Balugrastim Low Dose","type":"EXPERIMENTAL","interventionNames":["Biological: Balugrastim","Drug: Chemotherapy Regimen"]},{"label":"Pilot Phase: Balugrastim Medium Dose","type":"EXPERIMENTAL","interventionNames":["Biological: Balugrastim","Drug: Chemotherapy Regimen"]},{"label":"Pilot Phase: Balugrastim High Dose","type":"EXPERIMENTAL","interventionNames":["Biological: Balugrastim","Drug: Chemotherapy Regimen"]},{"label":"Pilot Phase: Pegfilgrastim","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pegfilgrastim","Drug: Chemotherapy Regimen"]},{"label":"Main Phase: Balugrastim Medium Dose","type":"EXPERIMENTAL","interventionNames":["Biological: Balugrastim","Drug: Chemotherapy Regimen"]},{"label":"Main Phase: Balugrastim High Dose","type":"EXPERIMENTAL","interventionNames":["Biological: Balugrastim","Drug: Chemotherapy Regimen"]},{"label":"Main Phase: Pegfilgrastim","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pegfilgrastim","Drug: Chemotherapy Regimen"]}],"interventions":[{"name":"Balugrastim","otherNames":["Neugranin"]},{"name":"Pegfilgrastim","otherNames":[]},{"name":"Chemotherapy Regimen","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Breast cancer participants scheduled to receive the AT regimen (doxorubicin/ docetaxel).\n\nExclusion Criteria:\n\n* Participants may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Severe Neutropenia in Cycle 1","description":"Severe neutropenia was defined as Grade 4 neutropenia (absolute neutrophil count \\[ANC\\] \\<0.5 x 10\\^9/liter \\[L\\]). The duration of severe neutropenia was calculated by cycle as the number of days from the first day in which the ANC fell below 0.5 x 10\\^9/L after beginning a chemotherapy cycle until the participant had an ANC ≥0.5 x 10\\^9/L within the cycle.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.37"},{"groupId":"OG001","value":"1.6","spread":"1.83"},{"groupId":"OG002","value":"1.1","spread":"1.48"},{"groupId":"OG003","value":"0.9","spread":"1.13"},{"groupId":"OG004","value":"1.0","spread":"1.09"},{"groupId":"OG005","value":"1.3","spread":"1.22"},{"groupId":"OG006","value":"1.2","spread":"1.34"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Febrile Neutropenia","description":"Febrile neutropenia was defined as an imputed or observed ANC \\<0.5 x 10\\^9/L and oral temperature ≥38.2 degrees celsius (°C) occurring on the same day. Number of participants with febrile neutropenia over all cycles (Cycles 1 to 4) has been reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"5","spread":null},{"groupId":"OG006","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Severe Neutropenia in Cycles 2, 3, and 4","description":"Severe neutropenia was defined as Grade 4 neutropenia (ANC \\<0.5 x 10\\^9/L). The duration of severe neutropenia was calculated by cycle as the number of days from the first day in which the ANC fell below 0.5 x 10\\^9/L after beginning a chemotherapy cycle until the participant had an ANC ≥0.5 x 10\\^9/L within the cycle.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"},{"groupId":"OG001","value":"0.8","spread":"1.22"},{"groupId":"OG002","value":"0.4","spread":"0.68"},{"groupId":"OG003","value":"0.5","spread":"0.88"},{"groupId":"OG004","value":"0.5","spread":"0.80"},{"groupId":"OG005","value":"0.4","spread":"0.80"},{"groupId":"OG006","value":"0.5","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.07"},{"groupId":"OG001","value":"0.7","spread":"0.92"},{"groupId":"OG002","value":"0.6","spread":"1.24"},{"groupId":"OG003","value":"0.3","spread":"0.61"},{"groupId":"OG004","value":"0.4","spread":"0.78"},{"groupId":"OG005","value":"0.5","spread":"1.00"},{"groupId":"OG006","value":"0.4","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.99"},{"groupId":"OG001","value":"0.3","spread":"0.77"},{"groupId":"OG002","value":"0.1","spread":"0.49"},{"groupId":"OG003","value":"0.7","spread":"1.25"},{"groupId":"OG004","value":"0.4","spread":"0.79"},{"groupId":"OG005","value":"0.6","spread":"1.06"},{"groupId":"OG006","value":"0.6","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Time to Absolute Neutrophil Count (ANC) Recovery in Cycles 1, 2, 3, and 4","description":"Time to ANC recovery was defined as the time from the nadir ANC to an ANC ≥1.5 x 10\\^9/L and was calculated for participants with ANC \\<1.5 x 10\\^9/L after the beginning of a chemotherapy cycle. Time to ANC recovery was calculated by cycle as the number of days from the nadir (the lowest ANC during a chemotherapy cycle) until a participant reached an ANC \\>1.5 x 10\\^9/L.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"2.38"},{"groupId":"OG001","value":"2.6","spread":"1.78"},{"groupId":"OG002","value":"2.0","spread":"1.26"},{"groupId":"OG003","value":"2.4","spread":"1.59"},{"groupId":"OG004","value":"2.0","spread":"0.94"},{"groupId":"OG005","value":"2.1","spread":"1.03"},{"groupId":"OG006","value":"2.6","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.58"},{"groupId":"OG001","value":"2.1","spread":"1.21"},{"groupId":"OG002","value":"1.9","spread":"0.79"},{"groupId":"OG003","value":"1.9","spread":"1.20"},{"groupId":"OG004","value":"1.8","spread":"0.80"},{"groupId":"OG005","value":"1.8","spread":"1.11"},{"groupId":"OG006","value":"2.1","spread":"1.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.46"},{"groupId":"OG001","value":"2.0","spread":"1.00"},{"groupId":"OG002","value":"2.2","spread":"1.39"},{"groupId":"OG003","value":"1.9","spread":"1.06"},{"groupId":"OG004","value":"1.9","spread":"1.08"},{"groupId":"OG005","value":"2.2","spread":"1.33"},{"groupId":"OG006","value":"1.8","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"1.68"},{"groupId":"OG001","value":"1.8","spread":"0.83"},{"groupId":"OG002","value":"1.3","spread":"0.49"},{"groupId":"OG003","value":"2.3","spread":"1.49"},{"groupId":"OG004","value":"1.9","spread":"0.85"},{"groupId":"OG005","value":"2.1","spread":"1.16"},{"groupId":"OG006","value":"2.1","spread":"1.27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":10},"commonTop":["Alopecia","Neutropenia","Nausea","Asthenia","Leukopenia"]}}}